Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04086212

Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine

Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine Compared to Icodextrin Alone, an Exploratory Study.

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Iperboreal Pharma Srl · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Randomized, cross-over, controlled, open label study. The aim of this study is to demonstrate that glucose may completely be replaced by a combination of xylitol and carnitine in the bimodal PD solution for long dwell exchange.

Detailed description

The use of a solution icodextrin, xylitol and carnitine (IXC) as the osmotic agent in dialysate for the long dwell exchange provides sustained ultrafiltration (UF) through colloid osmosis, allowing a consistent reduction in extracellular fluid volume without the expected fall in urine output. The other major advantage of IXC is the reduced exposure and absorption of glucose as the main osmotic agent in PD therapy. The aim of this study is to demonstrate that glucose may completely be replaced by a combination of xylitol and carnitine in the bimodal IXC-based PD solution. Compared to glucose, indeed, carnitine and xylitol are extremely stable naturally occurring compounds, even at temperatures higher than those used to steam-sterilize infusional product. As a consequence, xylitol and carnitine may represent better alternatives than glucose as an osmotic ingredient both from the manufacturing and biocompatibility standpoints. Moreover, xylitol and carnitine have an excellent safety profile and possess distinct systemic actions, which are more favorable than glucose.

Conditions

Interventions

TypeNameDescription
DRUGIcodextrin, xylitol and carnitine solution for peritoneal dialysisPatients will receive a long dwell exchange for three days.
DRUGEXTRANEAL 7.5G/100Ml Peritoneal Dialysis SolutionPatients will receive a long dwell exchange for three days.

Timeline

Start date
2019-10-02
Primary completion
2022-12-01
Completion
2023-04-01
First posted
2019-09-11
Last updated
2024-10-01

Source: ClinicalTrials.gov record NCT04086212. Inclusion in this directory is not an endorsement.